兔ATG联合环孢素与艾曲泊帕治疗输血依赖型再生障碍性贫血的II期研究
12周血液学总缓解率为52.6%(95%CI 39.0%-66.0%),26周升至67.9%。最常见3/4级不良事件为发热性中性粒细胞减少(20.0%),1例高龄重度中性粒细胞减少患者死于脓毒症。
要点
- 三联方案12周总缓解率52.6%,26周升至67.9%
- 发热性中性粒细胞减少是最常见3/4级不良事件(20.0%)
- 加用艾曲泊帕未诱发与不良预后相关的染色体异常
核心结论
- 兔ATG三联方案可能与人ATG方案疗效相当,加用艾曲泊帕未诱导预后不良的染色体异常。
主要发现
- 12周血液学总缓解率为52.6%(95%CI 39.0%-66.0%),26周升至67.9%。
- 最常见3/4级不良事件为发热性中性粒细胞减少(20.0%),1例高龄重度中性粒细胞减少患者死于脓毒症。
- 分别有1例患者进展为MDS和1例进展为AML。
- 血液学缓解与高血小板生成素水平、PNH型细胞或HLA I类等位基因缺失细胞均无关联。
- 基线时5例(8.5%)存在染色体异常,未后续进展为MDS或AML;至26周8例(17.4%)出现新发或克隆扩大染色体异常,但52周内未观察到7号染色体异常。
临床怎么用
- 对于严重或输血依赖型非严重再生障碍性贫血,可考虑兔ATG联合环孢素和艾曲泊帕的三联方案。
- 治疗中需警惕发热性中性粒细胞减少,尤其高龄重度中性粒细胞减少患者应加强感染防控。
- 艾曲泊帕联合兔ATG方案未增加预后不良染色体异常风险,但仍需监测染色体核型变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The efficacy of a triple combination of rabbit anti-human thymocyte immunoglobulin (rATG), ciclosporin and eltrombopag (EPAG) was prospectively evaluated in patients with severe or transfusion-dependent non-severe aplastic anaemia (SAA) across 29 institutions in Japan. Sixty patients were enrolled, of whom 48 had SAA. The primary end-point, the haematological overall response rate at 12 weeks, was 52.6% (95% confidence interval, 39.0%-66.0%), increasing to 67.9% at 26 weeks. The most frequent grade 3/4 adverse event was febrile neutropenia (20.0%). One elderly patient with severe neutropenia died of sepsis. Progression to myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML) was observed in one patient each. There was no association between the haematological response and high thrombopoietin levels, presence of paroxysmal nocturnal haemoglobinuria-type cells or Human Leukocyte Antigen (HLA) class I allele-lacking cells. Five patients (8.5%) had chromosomal abnormalities at baseline with no subsequent progression to MDS or AML. By 26 weeks, chromosomal abnormalities had emerged or expanded in eight patients (17.4%), although abnormalities of chromosome 7 were not observed within 52 weeks. These results suggest that triple therapy with rATG may be as effective as that with horse anti-human thymocyte immunoglobulin. Notably, the addition of EPAG did not induce chromosomal abnormalities associated with poor prognosis.
引用
- Nakamura F, Ishiyama K, Suzuki R, et al. Phase II study of the triple combination of rabbit ATG, ciclosporin and eltrombopag in patients with transfusion-dependent aplastic anaemia: West Japan Hematology Study Group (W-JHS) AA02 trial. Br J Haematol. 2026. PMID: 41485764. doi:10.1111/bjh.70307
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。